American Medical Innovation and Investment Act of 2024
A BILL
To amend title XVIII of the Social Security Act to provide for a cognitive impairment detection benefit under the Medicare program, and for other purposes.
Sec. 2 Cognitive impairment detection benefit in the Medicare annual wellness visit and initial preventive physical examination
“(D) Detection of any cognitive impairment that shall—
“(i) be performed using one of the cognitive impairment detection tools identified by the National Institute on Aging as meeting its criteria for selecting instruments to detect cognitive impairment in the primary care setting; and
“(ii) include documentation of the tool used for detecting cognitive impairment and results of the assessment in the patient’s medical record.”
Sec. 3 Improving the national and local coverage determination processes under the Medicare program
“(7) Limitation on duration of coverage with evidence development determinations
“(A) In general—Subject to subparagraph (B), in the case of a final decision under paragraph (3)(C)(i) (including any such decision made on a class-wide basis) made on or after the date of the enactment of this paragraph that results in coverage of an item or service pursuant to subsection (a)(1)(E), the Secretary shall, not later than 10 years after the date on which such coverage becomes effective pursuant to such subsection, initiate a redetermination with respect to such item or service.
“(B) Exception—The Secretary may delay a redetermination described in subparagraph (A) with respect to an item or service for a period of time determined appropriate by the Secretary if—
“(i) the Secretary finds that such item or service is reasonable and necessary to carry out the purposes described in section 1142; or
“(ii) the entity responsible for such item or service requests such extension.
“(C) Posting of information—Not later than 1 year after the date of the enactment of this paragraph, and annually thereafter, the Secretary post on the public website of the Centers for Medicare & Medicaid Services the following information:
“(i) The number of items and services covered under this title pursuant to subsection (a)(1)(E).
“(ii) A description of each such item or service.
“(iii) The year in which coverage of each such item or service became effective pursuant to such subsection.”
“(8) Requirement to provide explanation in case of certain rejected requests—With respect to each document received by the Secretary on or after the date that is 1 year after the date of the enactment of this paragraph that identifies itself as a complete, formal request for a national coverage determination (as described in the notice entitled “Medicare Program; Revised Process for Making National Coverage Determinations” (78 Fed. Reg. 48164) or a successor regulation), the Secretary shall, not later than 90 days after receipt of such document—
“(A) determine whether such document is a complete, formal request for a national coverage determination; and
“(B) in the case that the Secretary finds that such document is not a complete, formal request for a national coverage determination, transmit to the entity submitting such document information on such finding that includes a specification of additional information needed to make such document a complete, formal request for a national coverage determination.”
“(E) Ensuring consistency with applicable rules—The Secretary shall require each Medicare administrative contractor that develops a local coverage determination to ensure that any such local coverage determination does not conflict with any law, ruling, regulation, national coverage determination, payment policy, or coding policy.”
Sec. 4 Medicare coverage of external infusion pumps and non-self-administrable home infusion drugs
“(1) The prescribing information approved by the Food and Drug Administration for the home infusion drug associated with the pump instructs that the drug should be administered by or under the supervision of a health care professional.
“(2) A qualified home infusion therapy supplier (as defined in subsection (iii)(3)(D)) administers or supervises the administration of the drug or biological in a safe and effective manner in the patient’s home (as defined in subsection (iii)(3)(B)).
“(3) The prescribing information described in paragraph (1) instructs that the drug should be infused at least 12 times per year—
“(A) intravenously or subcutaneously; or
“(B) at infusion rates that the Secretary determines would require the use of an external infusion pump.”